NGeneBio Co

NGeneBio Co EBIT Growth

The Year-over-Year EBIT Growth of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is 48.20 %. In the previous year, Year-over-Year EBIT Growth was -18.20 % — a change of -364.84% (higher).

EBIT Growth

48.20 %

YoY

-364.84%

Last updated:

Year-over-Year EBIT Growth of NGeneBio Co is 2025 48.20 % . Year-over-Year EBIT Growth of NGeneBio Co was 2024 -18.20 % . It decreases by -364.84% higher compared to the previous year.

The NGeneBio Co EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2019
-21.57 KRW
Jan 1, 2020
-40.21 KRW
Jan 1, 2021
-40.19 KRW
Jan 1, 2022
-0.92 KRW
Jan 1, 2023
-56.52 KRW
Jan 1, 2024
-18.20 KRW
Jan 1, 2025
48.20 KRW
The NGeneBio Co EBIT Growth history
YEAREBIT GrowthYoY
48.20 %-364.84%
-18.20 %-67.80%
-56.52 %+6,076.73%
-0.92 %-97.72%
-40.19 %-0.05%
-40.21 %+86.39%
-21.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

Year-over-Year EBIT Growth of NGeneBio Co is 48.20 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's NGeneBio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — NGeneBio Co

All Key Metrics — NGeneBio Co